The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.Crinetics Pharmaceuticals (CRNX 27.92%) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpriced. The U.S. Food and Drug Administration (FDA) approval on Sept. 25 transforms this clinical-stage company into a commercial powerhouse wit ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Vancouver, BC, Canada – TheNewswire - September 26, 2025 – First Tellurium Corp. (CSE: FTEL, OTCQB: FSTTF) (“First Tellurium” or the “Company”) reports that it has been requested by OTC Markets Group Inc. (“OTC Markets”) to issue this statement regarding recent promotional activity concerning the Company’s common shares traded on the OTCQB market. On September 22, 2025, OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and its shares, including t ...

BREAKING: Bullish Rebound Pares Market's Weekly Losses Shares of Crinetics Pharmaceuticals (CRNX) surged Friday after the Food and Drug Administration approved the company's acromegaly drug, Palsonify. Acromegaly is a rare condition in which the pituitary gland produces too much growth hormone. This causes some bones, organs and other tissues to grow bigger. The late wrestler and actor Andre Rene Roussimoff — widely known as "Andre the Giant" — suffered from acromegaly. Palsonify will cost $290,000 a year, ...

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday.Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.Also, Baird and JMP Securities raised their respective price targets on the stock.Crinetics Pharmaceuticals shares jumped 23.7% to $44.41 on Friday.Here are some other big stocks recording gains in today’s session.Aquestive Therapeutics, Inc. (NASDAQ: AQST) gained 21.2% to $6.38.Perpetua Resourc ...

智通财经APP获悉，周五，Crinetics(CRNX.US)盘初暴涨23%，创8个月新高，报44.30美元。消息面上， 此前FDA批准了其用于治疗肢端肥大症的药物，这是一种导致体内生长激素过多产生的罕见疾病。这种 名为Palsonify的药物是一种每日一次的口服治疗药物，公司预计它将在十月初在美国上市。此次批准基 于两项三期试验的数据，试验中药物耐受性良好，并带来了快速且一致的生化控制和症状减轻。 （原标题：美股异动 | Crinetics(CRNX.US)盘初暴涨23% FDA批准其生长激素紊乱治疗方案） ...

周五，Crinetics(CRNX.US)盘初暴涨23%，创8个月新高，报44.30美元。消息面上，此前FDA批准了其 用于治疗肢端肥大症的药物，这是一种导致体内生长激素过多产生的罕见疾病。这种名为Palsonify的药 物是一种每日一次的口服治疗药物，公司预计它将在十月初在美国上市。此次批准基于两项三期试验的 数据，试验中药物耐受性良好，并带来了快速且一致的生化控制和症状减轻。 ...

PresentationI will now turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead.Gayathri DiwakarSenior Director of Investor Relations Thank you, operator. Good afternoon, everyone, and thank you for joining us to discuss the FDA approval of PALSONIFY. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer; Dr. Dana Pizzuti, Chief Medical and Development Officer; and Isabel Kalofonos, Chief Commercial Officer. In addition, Tobin Schilke, Chief Financial ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) FDA Announcement September 25, 2025 06:00 PM ET Company ParticipantsGayathri Diwakar - Senior Director - IRR. Scott Struthers - President, Co-Founder, CEO & DirectorDana Pizzuti - Chief Medical & Development OfficerIsabel Kalofonos - Chief Commercial OfficerJosh Schimmer - Managing DirectorTobin Schilke - CFOGavin Clark-Gartner - MD - Biotechnology Equity ResearchJoseph Schwartz - Senior MD - Rare DiseasesSelena Zhang - Global capital marketsAlan Krasner - Chief End ...